ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

According to a long-term follow-up analysis of a phase I/II trial, bosutinib provides durable responses and a favorable toxicity profile in patients with chronic phase CML who are resistant/intolerant to other tyrosine kinase inhibitors.

Expression levels of CD62L and related immunologic markers are correlated with treatment responses and outcome in patients with CML, according to a new analysis. The markers could have prognostic value if validated in other cohorts.

Patients with chronic myeloid leukemia with a history of prior malignancies generally fare as well as those without such a history, according to a new study.

An analysis of tyrosine kinase inhibitor initiation and adherence in Medicare beneficiaries with chronic myeloid leukemia suggests that out-of-pocket costs may be a barrier to treatment.

The STIM1 study shows that patients with chronic myeloid leukemia who have undetectable minimal residual disease can safely discontinue imatinib therapy.

A study found that the protein EZH2 is required for chronic myeloid leukemia initiating cells to survive. Inhibiting EZH2 could improve outcomes in TKI-resistant disease.

Data from the large, population-based EUTOS registry showed strong survival outcomes in patients with CML, and validated risk scores as prognostic of outcome.

Pages

Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.